Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, indicating a challenging financial outlook for the upcoming year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to range from -90.56 million to -74.09 million yuan for 2025 [1] - Projected operating revenue for the same period is estimated to be between 198.31 million and 242.38 million yuan [1] Business Operations - During the reporting period, the company's production and operational activities were normal, with a slight increase in sales revenue and volume for the product Su Tai [1] - The revenue from the product Shutaqing has decreased due to external environmental factors and industry policies, prompting the company to explore multiple channels for market expansion [1] Product Development - The company is focusing on marketing efforts for its polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Sitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yiqing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shu Changqing)" [1] Non-recurring Gains and Losses - The company expects non-recurring gains and losses for 2025 to be approximately 4.75 million yuan, with specific figures to be disclosed in the annual report [1]

3月25日，舒泰神对外披露了公司2024年年报。财务数据显示，公司报告期内实现的营业收入约为3.25亿元，同比下降10.81%；对应实现的归属净利润约 为-1.45亿元，上年同期为-3.99亿元，同比实现减亏。 压缩研发难救业绩，舒泰神净利连亏五年 得益于研发投入大幅缩减，舒泰神（300204）2024年净利得以减亏。不过，公司仍未实现盈利，归属净利润已连续亏损五年。在业绩连亏下，仅靠缩减研发 成本并不能根本性扭转公司的经营困局，下一步如何提振业绩，还需要公司管理层动一番脑筋。 在北京中医药大学卫生健康法治研究与创新转化中心主任邓勇看来，药企在业绩持续亏损下，可以合理规划研发项目，集中资源推进重点产品研发。同时， 加强内部管理，优化研发、生产、运营等环节成本，提高资金使用效率，减少不必要开支。此外，可以与其他企业、科研机构开展战略合作，共享资源、降 低成本、加快研发进度；可探索多元化发展战略，如拓展业务领域、开展技术服务等增加收入来源。 针对公司相关问题，北京商报记者向舒泰神方面发去采访函，截至记者发稿未收到公司回复。 北京商报记者 丁宁 舒泰神表示，受外部环境及行业政策等因素影响，公司主要产品的销售收入有所 ...